Takeda Pharmaceutical Co ADR (NYSE:TAK) currently has a daily average trading volume of 1.87M but it saw 4508641 shares traded in last market. With a market cap of 45.46B USD, the company’s current market price of $14.34 came rising about 1.99 while comparing to the previous closing price of $14.06. In past 52 weeks, the stock remained buoying in the range of price level as high as $15.37 and as low as $12.57. In the recent trading on the day, stock has struck highest price mark of $13.69 while lowest mark touched by it was $14.385.
Taking a look at 20-day trading activity of Takeda Pharmaceutical Co ADR (TAK) gives us an average price of $14.93, while its current price level is -6.70% below from 52-week high level whereas it is 14.04% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $14.40 while that of 200 days or SMA-200 reads an average of $13.97. A closer look into the stock’s movement over the week reveals that its volatility is standing at 3.69% during that period while stretching the period over a month that decreases to 1.75%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 41.56 which implies that the stock is in neutral territory.
BofA Securities upgraded its recommendation for the stock as a “Buy” from “Neutral” on March 16, 2023 while assigning a price target of $20. Cowen also issued its recommendations for the stock as it upgraded the price target for the stock in the range of between $21 and $24.
Over the week, TAK’s stock price is moving -4.27% down while it is -3.76% when we observe its performance for the past one month. Year-to-date it is 8.31% up and over the past year, the stock is showing an upside performance of 4.90%.
The company is expected to be releasing its next quarterly report on 2025-Jan-29, for which analysts forecasted an EPS of 0 while estimate for next year EPS is 0. In next quarter, company is expected to be making quarterly sales of $1.15T as analysts are expecting the sales for current fiscal year at $4.61T and seeing the company making $4.61T in sales next year. Moreover, analysts are in estimates of $1.08T for current-quarter revenue.
Currently, Takeda Pharmaceutical Co ADR’s total number of outstanding shares is 3.17B with 0.01% of that held by the insiders while 2.33% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at 1.77% and return on equity (ROE) at 2.87%. It has a price to earnings ratio (P/E ratio) of 33.73 while having a 28.86 of forward P/E ratio. Stock’s beta reads 0.31. Stock has a price to book (P/B) ratio of 0.96 while price to sale or P/S ratio amounts to 1.50. Its return on asset (ROA) is 1.38% on average.
